Journal of Medicinal Chemistry · 2004 · 188 citations · 15 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryLead OptimizationStructure-activity RelationshipsFragment-based Drug DesignFragment-based Lead DiscoveryFragment-based OptimizationHit-to-lead OptimizationLead DiscoveryPotency OptimizationBinding Mode OptimizationChemical Structure-activity RelationshipsFragment OptimizationFragment-based Lead DesignFragment-based Lead OptimizationStructure-based Lead DiscoveryStructure-guided DesignStructure-guided Lead Discovery
We describe the structure-guided optimization of the molecular fragments 2-amino-3-benzyloxypyridine 1 (IC(50) 1.3 mM) and 3-(2-(4-pyridyl)ethyl)indole 2 (IC(50) 35 microM) identified using X-ray crystallographic screening of p38alpha MAP kinase. Using two separate case studies, the article focuses on the key compounds synthesized, the structure-activity relationships and the binding mode observations made during this optimization process, resulting in two potent lead series that demonstrate significant increases in activity. We describe the process of compound elaboration either through the growing out from fragments into adjacent pockets or through the conjoining of overlapping fragments and demonstrate that we have exploited the mobile conserved activation loop, consisting in part of Asp168-Phe169-Gly170 (DFG), to generate significant improvements in potency and kinase selectivity.
15
Fragment-Based Lead Discovery Using X-ray Crystallography
Michael J. Hartshorn, Christopher W. Murray, Anne Cleasby et al. · Journal of Medicinal Chemistry · 2004 · 423 citations